Ackman’s Pershing Square Holdings Loses 15.9% on Valeant

Updated on
Key Speakers At The 20th Annual Sohn Investment Conference

Bill Ackman, founder and chief executive officer of Pershing Square Capital Management LP.

Photographer: Andrew Harrer/Bloomberg

Pershing Square Holdings, the publicly traded security of Bill Ackman’s activist hedge fund, extended losses over the past week amid attacks on Valeant Pharmaceuticals International Inc., bringing its decline this year to 15.9 percent.

The latest returns, reported weekly, are as of Oct. 27. The year-to-date decline as of Oct. 20 was 11.2 percent, according to Pershing Square Holdings’ website.

Drugmaker Valeant plunged after a short-seller last week accused the company of wrongdoing. Pershing Square owns more than 5 percent of the company, and added more than 2 million shares to that stake during the recent rout. Valeant has denied charges of accounting and ethical irregularities.

The Amsterdam-traded portfolio that began trading in October 2014 mirrors Pershing Square’s hedge fund holdings, with stakes in public companies including animal-health company Zoetis Inc., Canadian Pacific Railway Ltd. and Air Products & Chemicals Inc.

Watch Next: Citron's Left Says What Valeant's Doing 'Sounds Illegal'

Citron's Left: What Valeant's Doing 'Sounds Illegal'
Before it's here, it's on the Bloomberg Terminal. LEARN MORE